50th week of 2019 patent applcation highlights part 21 |
Patent application number | Title | Published |
20190375804 | MODULAR RESILIN-MIMETIC ELASTOMERIC PLATFORM - Disclosed herein is a synthetic polypeptide with “n” number of repeats of a sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. The synthetic polypeptide as disclosed herein is represented by an amino acid sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5. The synthetic polypeptide of the present disclosure is used to prepare synthetic elastomeric hydrogel. Also, disclosed are the methods of preparing the synthetic polypeptide and the elastomeric hydrogel along with their uses. | 2019-12-12 |
20190375805 | NAF-1 DERIVED PEPTIDES AND USES THEREOF - The present invention provides peptides comprising a sequence derived from the human NAF-1 protein, analogs of said sequence or a retro-inverso sequence of said peptide or analog. The conjugates of such peptides are provided as well. The peptides and the conjugates of the present invention are useful in treating cancer, and in particular cancer in which the expression of NAF-1 is enhanced. | 2019-12-12 |
20190375806 | METHOD OF TREATING BREAST CANCER - The present disclosure provides for and relates to novel fusion proteins and polypeptides expressed by breast cancer and other cancer cells, and to compositions, materials and methods for detecting, characterizing and treating said breast and other cancers. In one embodiment, the fusion polypeptides are read-through fusion transcripts. | 2019-12-12 |
20190375807 | MODIFIED LIGAND-GATED ION CHANNELS AND METHODS OF USE - This document relates to materials and methods for controlling ligand gated ion channel (LGIC) activity. For example, modified LGICs including at least one LGIC subunit having a modified ligand binding domain (LBD) and/or a modified ion pore domain (IPD) are provided. Also provided are exogenous LGIC ligands that can bind to and activate the modified LGIC, as well as methods of modulating ion transport across the membrane of a cell of a mammal, methods of modulating the excitability of a cell in a mammal, and methods of treating a mammal having a channelopathy. | 2019-12-12 |
20190375808 | ANALOGUES OF VDAC1-DERlVED PEPTIDES - The present invention relates to peptides comprising analogues of VDAC1-derived peptides having improved pharmacokinetic characteristics compared to the native parent peptides, which are effective in impairing cell energy production, in inducing apoptosis and cell death, particularly of cancerous cells, in eliminating cancer stem cells and in reducing symptoms associated with fat accumulation in liver cells particularly with nonalcoholic fatty liver disease (NAFLD) and symptoms associated thereto | 2019-12-12 |
20190375809 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2019-12-12 |
20190375810 | USE OF ERYTHROPOIETIN-DERIVED PEPTIDE THROUGH EFFECT ON CELL DAMAGE PREVENTION THEREOF - A peptide is described herein that has: (i) a simple structure compared to existing natural human erythropoietin, thus capable of easily passing through a tissue-blood barrier, (ii) excellent bioactivity with respect to cell-protecting activity, (iii) a low manufacturing cost, thus being economically advantageous, and (iv) no side effects on cell proliferation. Also, a pharmaceutical composition comprising the erythropoietin-derived peptide described herein as an active ingredient is described. The pharmaceutical composition may be used for preventing or treating cell damage-related illnesses, such as stroke, mechanical damage or ischemic damage to the nervous system, myocardial infarction, retinal damage, and diabetes. Also, the described pharmaceutical composition may be used for preventing cell damage. | 2019-12-12 |
20190375811 | COMPOSITIONS COMPRISING LENTIVIRAL VECTORS EXPRESSING IL-12 AND METHODS OF USE THEREOF - This patent application relates generally to the treatment of cancer, and more particularly to the use of a pseudotyped lentivirus expressing IL-12 for the treatment of cancer. | 2019-12-12 |
20190375812 | MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - This invention provides for a fusion protein between an IL2αβγ Selective Agonist protein (IL2 Selective Agonist) and a IgG Fc protein. The IL2 Selective Agonist moiety provides a therapeutic activity by selectively activating the IL2αβγ form of the receptor, thus selectively stimulating Tregs. The Fc moiety provides a prolonged circulating half-life compared to the circulating half-life of IL-2 or an IL2SA protein. | 2019-12-12 |
20190375813 | INSULIN ANALOGUES WITH SELECTIVE SIGNALING PROPERTIES AND REDUCED MITOGENICITY - A two-chain insulin analogue contains Aspartic Acid at position B10 and penta-fluoro-Phenylalanine at position B24, optionally Histidine or Glutamic Acid at position A8, optionally additional substitutions or modifications at positions A13 and/or A14 and/or B28 and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin, may optionally include (i) N-terminal deletion of one, two or three residues from the B chain, (ii) a mono-peptide or dipeptide C-terminal extension of the B-chain containing at least one acidic residue, and (iii) other modifications known in the art to enhance the stability of insulin. Formulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions at at least pH value in the range 7.0-8.0 in the absence or presence of zinc ions at a molar ratio of 0.00-0.10 zinc ions per insulin analogue monomer. | 2019-12-12 |
20190375814 | BIPHASIC SINGLE-CHAIN INSULIN ANALOGUES - A single-chain insulin comprises a C-domain of 6 to 11 amino acid residues comprising at least two acidic residues at the N-terminal side of the C-domain and at least two basic residues at the C-terminal side of the C-domain peptide, a basic amino acid residue at the position corresponding to A8 of human insulin, and an acidic amino acid residue at the position corresponding to A14 of human insulin. The C-domain may contain a 2 to 4 amino acid joint region between the acidic and basic residues. Residues C1 and C2 may have a net negative charge of −1 or −2; and the remaining C-domain segment may culminates with two basic residues. A pharmaceutical composition comprises the single-chain insulin, formulated at a pH within the range 7.0 to 8.0, and may be formulated at a concentration of 0.6 mM to 5.0 mM and/or at a strength of U-100 to U-1000. | 2019-12-12 |
20190375815 | TREATMENT OF CANCER USING CHIMERIC T CELL RECEPTOR PROTEINS HAVING MULTIPLE SPECIFICITIES - The present invention features the use of chimeric CD3 proteins to modulate T cell Receptor (TCR) signaling. Specifically, the invention is based, in part, on the discovery that multiple chimeric CD3 proteins (e.g., CD3delta, CD3gamma, and CD3 epsilon) having all or most of their extracellular domain fused to more than one antigen binding domain can activate the TCR in the presence of one or more cognate antigens. The invention is further based on the observation that the above chimeric proteins can be potentiated through the inclusion of a co-stimulatory domain in the intracellular portion of the chimeric molecule. Thus, the preferred elements of the engineered signaling complexes of the invention include more than one antigen binding domain, an extracellular domain derived from one of the above CD3 proteins, and an intracellular co-stimulatory domain. | 2019-12-12 |
20190375816 | HIGH AVIDITY ANTIGEN RECOGNIZING CONSTRUCTS - The present invention pertains to novel high avidity antigen recognizing constructs, such as antibodies or T cell receptors, which specifically bind to the melanoma associated antigen (MAGE) A1. The constructs of the invention are particularly useful for the diagnosis, prevention or therapy of tumorous diseases which are characterized by the specific expression of the MAGE-A1 antigen. Furthermore provided are nucleic acids, vectors and host cells—such as CD4 or CD8 positive T cells—which encode, comprise or present the antigen recognizing constructs of the invention. The invention thus provides new means for immune therapy, specifically adoptive T cell therapy, for treating cancer. | 2019-12-12 |
20190375817 | COMPOSITIONS AND METHODS OF MUSCLE SPECIFIC KINASE CHIMERIC AUTOANTIBODY RECEPTOR CELLS - The invention includes a chimeric autoantibody receptor (CAAR) specific for anti-muscle-specific kinase (MuSK) B cell receptor (BCR), compositions comprising the CAAR, polynucleotides encoding the CAAR, vectors comprising a polynucleotide encoding the CAAR, and recombinant cells comprising the CAAR. | 2019-12-12 |
20190375818 | COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF MELANOMA USING PD-L1 ISOFORMS - The present invention relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. A variety of PD-L1 isoform biomarkers are provided, wherein alterations in the copy number of one or more of the biomarkers and/or alterations in the amount, structure, and/or activity of one or more of the biomarkers is associated with melanoma status. | 2019-12-12 |
20190375819 | GLYCOSYLATED TRANSFERRIN RECEPTOR 1 TUMOR ANTIGEN - This invention relates to compositions and methods for treating or diagnosing cancer. | 2019-12-12 |
20190375820 | ALK7:ACTRIIB HETEROMULTIMERS AND USES THEREOF - In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. | 2019-12-12 |
20190375821 | CANCER TREATMENT COMPOSITION FOR INHIBITING TUMOR ANGIOGENESIS, CONTAINING VEGF DEEP BLOCKER, AND PREPARATION METHOD THEREFOR - The present invention relates to a cancer treatment composition for inhibiting angiogenesis, and a preparation method therefor. An angiogenesis inhibitor according to the present invention is a cancer treatment composition comprising a fusion protein comprising a vascular endothelial growth factor-binding domain of vascular endothelial growth factor receptor 1 (VEGFR1) and a b1 domain of neuropilin-1 (NRP1). The novel fusion protein is an angiogenesis inhibitor for blocking the binding of VEGF to a receptor in the cell membrane, and has an effect of inhibiting the proliferation of cancer cells and the growth and metastasis of cancer. In addition, the fusion protein can be used as an anti-cancer agent and exhibits an effective anti-cancer effect at a lower dose than that of a conventional angiogenesis inhibitor. | 2019-12-12 |
20190375822 | METHODS OF TREATING HEMOPHILIA A - The present disclosure provides a method of treating hemophilia A in a human subject in need thereof comprising administering to the subject a chimeric polypeptide comprising (i) a factor VIII (FVIII) protein and (ii) a von Willebrand factor (VWF) fragment comprising a D′ domain of VWF and a D3 domain of VWF at a dosing interval. | 2019-12-12 |
20190375823 | MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS - Provided herein are multifunctional heteromultimer proteins. In specific embodiments is a heteromultimer comprising: at least two polypeptide constructs, each polypeptide construct comprising at least one cargo polypeptide attached to a transporter polypeptide, said transporter polypeptides derived from a monomeric native protein such that said monomeric constructs associate to form the heteromultimer and said transporter polypeptides associate to form a quasi-native structure of the monomeric native protein or analog thereof. These therapeutically novel molecules encompass heteromultimers comprising constructs that function as scaffolds for the conjugation or fusion of therapeutic molecular entities (cargo polypeptides) resulting in the creation of bispecific or multivalent molecular species. Provided herein is a method for creation of bispecific or multivalent molecular species. | 2019-12-12 |
20190375824 | VHH ANTIBODY - Provided is a VHH antibody including an amino acid sequence in which at least one selected from the group consisting of glycine in position 36, arginine in position 50, and glycine in positon 78, on the basis of IMGT numbering, of the amino acid sequence represented by SEQ ID NO: 1 is substituted with another amino acid. The VHH antibody according to the present disclosure is thermostable. | 2019-12-12 |
20190375825 | ANTIBODIES THAT POTENTLY NEUTRALIZE RSV AND USES THEREOF - The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection. | 2019-12-12 |
20190375826 | ANTI-DENGUE VIRUS ANTIBODIES AND APPLICATIONS THEREOF - The present invention relates to anti-virus dengue virus antibodies and applications thereof. Specifically, the anti-virus dengue virus antibodies of the present invention are serotype specific and useful for specific detection and differentiation of various dengue virus serotypes in a biological sample. The present invention also provide methods and kits for detecting dengue virus and methods and compositions for use in diagnosis and treatment of dengue virus disease using the anti-virus dengue virus antibodies as described herein. | 2019-12-12 |
20190375827 | ANTIBODY AND ANTIBODY-CONTAINING COMPOSITION - For many diseases due to microbes or the like, proliferation of microbes themselves is a cause of a symptom. However, there were cases where a substance released by the microbes is a cause of a symptom. In such cases, when attempting to treat a disease with an antibody, it was necessary to obtain an antibody against an antigen that is a substance causing the disease. However, it was difficult to find the underlying substance causing the disease among substances released by the microbes. An antibody (polyclonal) binding to not only an antigen but also to a substance, which is secreted by the antigen and accelerates the deterioration of a symptom, is obtained by immunizing birds with a lysis solution produced from lysing microbial cells as an antigen. Further, an antibody obtained with a surface protein of a virus as an antigen is expected to inhibit an infection by a virus. | 2019-12-12 |
20190375828 | Antibodies that Neutralize Botulinum Neurotoxins - This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 2019-12-12 |
20190375829 | TAU-BINDING ANTIBODIES - The present invention relates to Tau-binding antibodies and binding fragments thereof. | 2019-12-12 |
20190375830 | ANTIBODY AND ANTIGEN-BINDING FRAGMENT COMPOSITIONS TARGETING CELL SURFACE ANTIGENS IN TUMORS AND METHODS OF USE THEREOF - Described herein is an isolated antibody or antigen-binding fragment including a heavy chain variable region including three heavy chain complementary determining regions (HCDRs), wherein the sequence of HCDR1 is GYRLSELS (SEQ ID NO: 1), the sequence of HCDR2 is ISGWDGNT (SEQ ID NO: 2), and the sequence of HCDR3 is ARASGYNY (SEQ ID NO: 3), wherein the isolated antibody or antigen-binding fragment specifically binds human HSP90, specifically HSP90 beta. Also included are detection and therapeutic methods using the isolated antibodies or antigen-binding fragments. | 2019-12-12 |
20190375831 | NEUTRALIZING ANTIBODIES TO PLASMODIUM FALCIPARUM CIRCUMSPOROZOITE PROTEIN AND THEIR USE - Antibodies and antigen binding fragments that specifically bind to | 2019-12-12 |
20190375832 | GARP-TGF-BETA 1 ANTIBODIES - The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability. | 2019-12-12 |
20190375833 | USE OF TGF-ALPHA POLYPEPTIDE OR ANTI-TGF-ALPHA ANTIBODIES FOR THE TREATMENT OF DISEASES AND DISORDERS - The invention provides a method of treating a disease or disorder in a subject by inducing a TGF alpha immune response or by administering an anti-TGF-alpha antibody or a biologically active fragment thereof. The TGF-alpha immune response is induced using a TGF-alpha polypeptide or biologically active fragment, a vaccine, a genetic construct or a transformed cell, for example. | 2019-12-12 |
20190375834 | DISULFIDE-TYPE HMGB1-SPECIFIC ANTIBODY, METHOD FOR MEASURING DISULFIDE-TYPE HMGB1 AND KIT FOR SAID MEASUREMENT, AND MEASUREMENT METHOD CAPABLE OF QUANTITATING ALL OF HMGB1 MOLECULES INCLUDING REDUCED HMGB1, DISULFIDE-TYPE HMGB1 AND THROMBIN-CLEAVABLE HMGB1 AND KIT FOR SAID MEASUREMENT - The present invention provides antibodies that show specific reactivity to disulfide-type HMGB1. Furthermore, the present invention provides methods for specifically measuring disulfide-type HMGB1 using the antibodies, and kits or reagents for the measurement. The present invention also provides methods for measuring total HMGB1 using such an antibody and an antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1, and kits or reagents for the measurement. | 2019-12-12 |
20190375835 | USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS - A composition includes monoclonal antibodies directed against a circulating proinflammatory cytokine, the antibodies having a high affinity for the FcγRIIIa receptor (CD16), in particular the fucose level of all of the antibodies of the composition being less than 60%, and preferably less than 50%, and in particular, the galactosylation level of all of the antibodies of the composition being at least 60%, for the use thereof in the context of the prevention or treatment of the early phases of inflammation. A composition including monoclonal antibodies directed against a circulating bacterial toxin, having an improved affinity for the FcγRIIIa receptor (CD16) with respect to antibodies directed against the bacterial toxin, produced in the CHO cell line, for the use thereof in the context of the prevention or treatment of the early phases of a bacterial infection linked to the release of the toxin is also described. | 2019-12-12 |
20190375836 | ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USE FOR THE TREATMENT OR PREVENTION OF TYPE 1 DIABETES - The present invention relates to compositions and methods utilizing anti-TNF antibodies having a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37 for use in the treatment or prevention of Type I Diabetes (T1D). | 2019-12-12 |
20190375837 | IMMUNOCYTOKINE COMBINATION THERAPY - This invention relates to methods and compositions, in a combination therapy, for treatment of neoplastic disease, including tumors and cancer, wherein an immunocytokine and a small molecule drug conjugate which comprises a moiety capable of binding to a tumor-associated target, e.g., capable of binding to carbonic anhydrase IX (CAIX), are administered. In preferred embodiments, the immunocytokine comprises an antibody targeting the ED-B or ED-A domain of fibronectin and interleukin-2, and the small molecule drug conjugate comprises a ligand moiety capable of binding to CAIX, a linker, and a cytotoxic drug. | 2019-12-12 |
20190375838 | PROTEINS BINDING BCMA, NKG2D AND CD16 - Multi-specific binding proteins that bind BCMA, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. | 2019-12-12 |
20190375839 | TIM-3 ANTIBODY, ANTIGEN BINDING FRAGMENT THEREOF, AND MEDICINAL USES THEREOF - A TIM-3 antibody, an antigen-binding fragment thereof, and medical uses thereof are described. More specifically, the present invention provides a rat-derived antibody containing a CDR region of the TIM-3 antibody, a chimeric antibody or a human-derived antibody thereof, and a pharmaceutical composition containing the TIM-3 antibody and the antigen-binding fragment thereof, as well as uses thereof serving as a drug. In particular, the present invention provides uses of a human-derived TIM-3 antibody in the preparation of drugs for treating TIM-3 -related conditions. | 2019-12-12 |
20190375840 | BINDING AGENTS - The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to CD47 (Cluster of Differentiation 47, also known as integrin associated protein [IAP]). In aspects of the invention, the anti-CD47 antibody molecules and antigen-binding portions thereof specifically bind to human CD47 and cynomolgus monkey CD47. Medical uses of the anti-CD47 antibody molecules and antigen-binding portions of the invention are disclosed. The anti-CD47 antibody molecules and antigen-binding portions of the invention represent modified and optimised binding molecules compared with a VxP037 murine/humanized anti-CD47 antibody described in WO2014/093678A2. | 2019-12-12 |
20190375841 | ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS - Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells. Further disclosed is a method of treating multiple myeloma using an anti-NTB-A antibody drug conjugate, which optionally includes an anti-NTB-A antibody as disclosed herein. | 2019-12-12 |
20190375842 | CHECK POINT INHIBITION IN ORGAN FIBROSIS - Disclosed are compositions and methods for treating pulmonary fibrosis with PD1 blockade, STAT3 inhibitors, IL-17 inhibitors, and/or TGFβ-1 inhibitors. | 2019-12-12 |
20190375843 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES - The present invention provides a newly identified B7 receptor, zB7R1 that functions as lymphocyte inhibitory receptor, which is a PD-1-like molecule and is expressed on T cells. The present invention also provides the discovery of zB7R1′s ability to bind to CD155. Methods and compositions for modulating zB7R1-mediated negative signaling and interfering with the interaction of its counter-receptor for therapeutic, diagnostic and research purposes are also provided. | 2019-12-12 |
20190375844 | ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127 - The invention is in the field of antibodies useful in therapeutic and diagnostics applications targeting CD127, the alpha chain of the IL7 receptor, and provides in particular humanized monoclonal antibodies against CD127, particularly human CD127, therapeutic uses thereof, and diagnostics applications. | 2019-12-12 |
20190375845 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND ENHANCING TUMOR VACCINES - The present invention provides methods of treating and enhancing efficacy of immunotherapy for a solid tumor in a subject, comprising the step of contacting the subject with a compound or composition that modulates the expression or activity of ETRB, ET-1, ICAM-1, or another protein found herein to play a role in homing of T cells to a solid tumor. The present invention also provides methods of prognosticating a solid tumor in a subject, comprising the step of measuring an expression level of a protein found herein to play a role in homing of T cells to a solid tumor, or a nucleotide molecule encoding same. | 2019-12-12 |
20190375846 | BINDING AGENTS - The invention relates to antibody molecules and antigen-binding portions thereof which bind specifically to glucocorticoid-induced TNF receptor (GITR). In particular aspects of the invention, the antibody molecules specifically bind to human GITR and cynomolgus monkey GITR. The anti-GITR antibody molecules of the invention have been developed and optimized using CDR sequences derived from a murine anti-GITR antibody 6C8. Medical uses of the antibody molecules are disclosed. | 2019-12-12 |
20190375847 | COMBINATION TREATMENT FOR CANCER - Disclosed herein is a method of treatment involving the combination of an anti-OX40 antigen binding protein (e.g., an anti-OX40 agonist antibody) and/or radiotherapy, for use in treating a cancer. The cancer may include anti-PD-1 resistance. | 2019-12-12 |
20190375848 | USE OF ANTI-TUMOUR EFFECTS OF A 'HUMAN & MOUSE CROSS-REACTIVE' ANTI-ADAM17 ANTIBODY IN TREATING PANCREATIC CANCER - Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of tumor amongst all human cancers due to late diagnosis and resistant to treatment with chemotherapy and radiation. Preclinical and clinical studies have revealed that ErbB family for example epidermal growth factor receptor (EGFR) is a validated molecular target for pancreatic cancer prevention and therapy. The ErbB signaling cascade is regulated by a member of the ADAM (a disintegrin and metalloprotease) family, namely ADAM17, by enzymatic cleavage of precursor ligands into soluble cytokines and growth factors. Mouse genetic studies have demonstrated that ADAM17 is required for PDAC development. In this study, we evaluated the anti-tumor effects of A9(B8) IgG—the first specific ‘human and mouse cross-reactive’ ADAM17 inhibitory antibody on pancreatic malignant transformation. We found that inhibition of ADAM17 with A9(B8) IgG efficiently suppressed the shedding of ADAM17 substrates both in vivo and in vitro. Furthermore, we demonstrated that administration of A9(B8) IgG significantly suppressed motility in human pancreatic cancer cells and also significantly delayed tumorigenesis in the Pdx1Cre;KrasG12D;Trp53fl/+ PDAC mouse model. Inhibition of ADAM17 with A9(B8) IgG particularly affected the progression of pre-invasive pancreatic lesions to advanced PDAC in mice. Taken together, the preclinical data presented here will provide a starting point for clinical applications of ADAM17 targeted therapy | 2019-12-12 |
20190375849 | MULTI-SPECIFIC BINDING PROTEINS FOR CANCER TREATMENT - The present invention relates to novel DLL3/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins; to compositions comprising such proteins; and to uses of such proteins or such compositions, in particular for therapeutic purposes in the field of cancer diseases. | 2019-12-12 |
20190375850 | EFFECTIVE GENERATION OF TUMOR-TARGETED T CELLS DERIVED FROM PLURIPOTENT STEM CELLS - The present invention relates to the field of adoptive immunotherapy. The invention provides methods for generating phenotypically defined, functional, and/or expandable T cells from pluripotent stem cells engineered through safe genetic modifications. The engineered cells may provide one or more of: 1) targeting a specific predetermined antigen expressed on the cell surface of a target cell in an HLA independent manner, 2) enhanced survival and functional potential 3) “off-the-shelf” T cells for administration to multiple recipients, eventually across immunogenic barriers, and/or 4) cytotoxic potential and anti-tumor activity. | 2019-12-12 |
20190375851 | Monoclonal Antibody Which Specifically Recognizes B Cell Lymphoma and Use Thereof - Provided is a monoclonal antibody which specifically recognizes B cell lymphoma cells and a use thereof. More specifically, provided are the monoclonal antibody; a pharmaceutical composition for preventing or treating B cell lymphoma including the monoclonal antibody; a composition for diagnosing B cell lymphoma including the monoclonal antibody; a method for providing information for diagnosing B cell lymphoma using the monoclonal antibody; a chimeric antigen receptor (CAR) protein including i) the antibody, ii) a transmembrane domain, and iii) an intracellular signaling domain; a recombinant vector which expresses the CAR protein; a CAR-modified T cell transformed with the recombinant vector; a pharmaceutical composition for preventing or treating B cell lymphoma including the CAR-modified T cell; and an antibody-drug conjugate wherein the monoclonal antibody and a drug are conjugated. | 2019-12-12 |
20190375852 | Combination Of T-Cell Redirecting Multifunctional Antibodies With Immune Checkpoint Modulators And Uses Thereof - The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and/or tumor-associated antigen; and (c) a binding site for human FcRI, FcγRIIa and/or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and/or FcγRIII than to human FcγRIIb. | 2019-12-12 |
20190375853 | USE OF ANTIBODY AGAINST O-ACETYLATED GD2 GANGLIOSIDE TO IMPROVE THE THERAPEUTIC POTENTIAL OF DRUGS - Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside. | 2019-12-12 |
20190375854 | MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF - Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from an anti-MUC16 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders. | 2019-12-12 |
20190375855 | ANTIGEN-BINDING PROTEINS TARGETING MELANOMA DIFFERENTIATION ANTIGENS AND USES THEREOF - The presently disclosed subject matter provides methods and compositions for treating cancer (e.g., melanoma). It relates to chimeric antigen receptors (CARs) that specifically target MDA (e.g., Trp1), and immunoresponsive cells comprising such CARs. The presently disclosed MDA-specific CARs have enhanced immune-activating properties, including anti-tumor activity. | 2019-12-12 |
20190375856 | ANTI-HtrA1 ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders. | 2019-12-12 |
20190375857 | COVALENT HETEROBIVALENT ANTIBODY INHIBITORS AND LIGANDS - The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies. | 2019-12-12 |
20190375858 | NOVEL CYCLODEXTRIN POLYMER WITH ULTRA-FAST ADSORPTION PERFORMANCE - A novel cyclodextrin polymer with ultra-fast adsorption performance is provided. A cyclodextrin polymer having a three-dimensional network structure is obtained by mixing and crosslinking a cyclodextrin with a rigid crosslinking agent and a non-rigid crosslinking agent at a certain temperature. The polymer is capable of adsorbing a plurality of organic pollutants in water at an ultra-fast rate, and the polymer after adsorption is easily regenerated by simple washing at a normal temperature, and is repeatedly used without causing a decrease in adsorption performance. | 2019-12-12 |
20190375859 | DEXTRAN SULFATE - Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (M | 2019-12-12 |
20190375860 | MODIFIED CARBOHYDRATES, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF MAKING AND USING THE SAME - Modified alginates are described herein along with hydrogels comprising the same. A modified alginate may be prepared by reacting alginate and an aromatic compound (e.g., an aromatic amine) and/or pH sensitive compound. The modified alginates, hydrogels, and/or methods described herein may be used to coat and/or encapsulate at least a portion of a bioactive substance, optionally for oral delivery in humans and other animals. | 2019-12-12 |
20190375861 | COMPOSITIONS AND METHODS FOR REMOVING CONTAMINANTS FROM PLASTICS PROCESSING EQUIPMENT - Compositions for removing contaminants from plastics processing equipment are described herein. The compositions may include a polymeric carrier component, an oxidizing agent, an abrasive and/or a gas agent. Methods of preparing the compositions described herein and methods of removing contaminants from plastics processing equipment are also described. | 2019-12-12 |
20190375862 | OFF-LINE FILTER FREE ZIEGLER-NATTA CATALYST PREPARATION - The various embodiments provide, a magnesium titanium polymerization procatalyst, and methods for making and using the same. | 2019-12-12 |
20190375863 | A PROCESS FOR REMOVING CHLORIDE FROM A POLYMER MELT - The present disclosure provides a process for removing chloride from a polymer melt using at least one adsorbent. The adsorbent is selected from a metal oxide mixture, a mixture of alumina and hydrotalcite, crystalline fajausite zeolite and alumina doped with at least one metal. The process of the present disclosure is carried out at a temperature in the range of 260° C. to 280° C., and at a pressure in the range of 120 bar to 160 bar for time period in the range of 12 hours to 200 hours. The amount of chloride adsorbed on the adsorbent is in the range of 0.1% to 6.0% w/w. | 2019-12-12 |
20190375864 | Articles Having Improved Clarity, Prepared from Propylene-Ethylene Copolymers - Molded articles are prepared from propylene-ethylene copolymers and exhibiting improved clarity and strength properties. Articles prepared include bottles and other thin-walled articles. The articles are prepared using an isotactic propylene-ethylene random copolymer resin having an ethylene content of from about 0.5 to about 3 percent by total weight of copolymer, with a xylene solubles content of less than about 1.5 percent. The injection molded article may exhibit less than about 20 percent haze, as determined by ASTM D1003, at a thickness of about 0.08 inch (2.03 mm). Articles may also be prepared from similar copolymers having an ethylene content greater than about 3 percent by total weight of copolymer, with a xylene solubles content of less than about 4 percent by total weight of copolymer. These articles may exhibit less than about 13 percent haze, as determined by ASTM D1003, at a thickness of about 0.08 inch (2.03 mm). | 2019-12-12 |
20190375865 | BINDER COMPOSITIONS AND METHODS OF PREPARING AND USING THE SAME - The present disclosure relates to compositions comprising a copolymer derived from a vinyl aromatic monomer, a (meth)acrylate monomer, an acid monomer, and a copolymerizable surfactant and compositions comprising the same. The (meth)acrylate monomer can be selected from a monomer having a theoretical glass transition temperature (Tg) for its corresponding homopolymer of 0° C. or less or a hydrophobic (meth)acrylate monomer. In some embodiments, the copolymer is further derived from an organosilane. The copolymers can have a theoretical glass transition temperature (Tg) from −60° C. to 80° C. and a number average particle size of 250 nm or less. The compositions can be used to prepare compositions such as coatings that have improved water resistance, blush resistance, and/or resistance to hydrostatic pressures. Methods of making the copolymers are also provided. | 2019-12-12 |
20190375866 | FLUOROPOLYMER POWDER AND METHOD FOR PRODUCING SAME - The invention provides a powder that is easily redispersible in a liquid medium such as water. The powder contains a fluoropolymer. The fluoropolymer contains at least one group A selected from the group consisting of —SO | 2019-12-12 |
20190375867 | FORMALDEHYDE-FREE THERMALLY CURABLE POLYMERS - Formaldehyde-free aqueous polymeric dispersions contain a triplet of functional monomers that, when submitted to heating, can crosslink, resulting in polymeric films without releasing formaldehyde or other hazardous materials, thus resulting in compositions with improved water and solvent resistance and bonding strength, suitable for applications such as textile coating, nonwovens, fiber bonding, paper coatings and impregnation, curable adhesives, industrial coatings and finishes and related applications. This triplet of functional monomers uses, at least, one amino- (or amido-), one epoxy- or hydroxy-, and one acid-functional monomer combination. | 2019-12-12 |
20190375868 | POLYMER HAVING A SMALL AVERAGE PARTICLE SIZE - The present invention relates to a polymer comprising: (a) polymeric units derived from vinyl chloride, vinyl acetate, styrene, methyl methacrylate, acrylonitrile, or combinations thereof; and 5 (b) polymeric units derived from one or more compounds according to formula I: wherein: R1 is CH3 or H; 10. R2 is a moiety comprising 1-20 carbon atoms; and. n is an integer from 1-10; wherein the polymer has. an average particle size of 10-80 μm expressed as D50 determined in accordance with ISO 9276-2 (2014); and 15 x a porosity of ≤0.20 ml/g as determined as the quantity of di(2-ethylhexyl)phthalate in ml absorbed by 1 g of polymer upon subjecting the polymer at 23° C. to vacuum, submerging in di(2-ethylhexyl)phthalate for 10 min, and subsequently centrifuging at 2000 rpm for 45 min. Such polymer may be used as viscosity reducing agent in PVC plastisol compositions. 20 | 2019-12-12 |
20190375869 | METHOD FOR PROVIDING AN ANTI-MICROBIAL AND AN ANTI-PILLING EFFECT AND FOR IMPROVING DYE UPTAKE TO TEXTILES, NOVEL CO-POLYMERS AND TEXTILES - The present invention relates to a method for providing an anti-microbial and an anti-pilling effect to textiles and for improving dye uptake to textiles. The invention also relates to novel co-polymers to be used in the method of the invention and to novel textiles. | 2019-12-12 |
20190375870 | METHOD OF PREPARING ACRYLONITRILE-BASED POLYMER FOR PRODUCING CARBON FIBER - A method of preparing an acrylonitrile-based copolymer for a carbon fiber. The method includes: preparing a reaction solution including a (meth)acrylonitrile-based monomer and a first reaction solvent; adding a first portion of a radical polymerization initiator to the reaction solution to initiate polymerization; and adding a second portion of the radical polymerization initiator to the reaction solution when a polymerization conversion ratio is between 70 to 80%. | 2019-12-12 |
20190375871 | COPOLYMERS AND USE THEREOF IN CLEANING-AGENT COMPOSITIONS - What are described are copolymers obtainable from the free-radical copolymerization at least of the following components:
| 2019-12-12 |
20190375872 | CONVEYOR BELT RUBBER COMPOSITION, METHOD FOR PRODUCING CONVEYOR BELT RUBBER COMPOSITION, CONVEYOR BELT, AND BELT CONVEYOR - An object of the present invention is to provide a conveyor belt rubber composition having excellent wear resistance and gouging resistance, a method for producing the conveyor belt rubber composition, a conveyor belt formed using the conveyor belt rubber composition, and a belt conveyor equipped with the conveyor belt. The present invention relates to a conveyor belt rubber composition containing a diene rubber containing less than 50 mass % of an aromatic vinyl-conjugated diene copolymer, wherein the aromatic vinyl-conjugated diene copolymer has a content of repeating units derived from an aromatic vinyl of 20 mass % or less, and a proportion of a vinyl structure in repeating units derived from a conjugated diene of 8 mol % or less. | 2019-12-12 |
20190375873 | CONVEYOR BELT RUBBER COMPOSITION, METHOD FOR PRODUCING CONVEYOR BELT RUBBER COMPOSITION, CONVEYOR BELT, AND BELT CONVEYOR - An object of the present invention is to provide a conveyor belt rubber composition having excellent cut resistance and wear resistance, a method for producing the conveyor belt rubber composition, a conveyor belt formed using the conveyor belt rubber composition, and a belt conveyor equipped with the conveyor belt. The present invention relates to a conveyor belt rubber composition containing a diene rubber containing 50 mass % or more of an aromatic vinyl-conjugated diene copolymer, wherein the aromatic vinyl-conjugated diene copolymer has a content of repeating units derived from an aromatic vinyl of more than 20 mass %, and a proportion of a vinyl structure in repeating units derived from a conjugated diene of 8 mol % or less. | 2019-12-12 |
20190375874 | RUBBERY POLYMER, GRAFT COPOLYMER, AND THERMOPLASTIC RESIN COMPOSITION - The thermoplastic resin composition contains a graft copolymer produced using a rubbery polymer having a high gel content. A molded article is produced by molding the thermoplastic resin composition. A rubbery polymer (A) that is a product of polymerization of a raw material mixture contains an alkyl (meth)acrylate, a crosslinking agent (1) represented by Formula (1) below, and a hydrophobic substance. The amount of the hydrophobic substance is 0.1 to 10 parts by mass relative to 100 parts by mass of the total amount of the alkyl (meth)acrylate and the crosslinking agent (1). The rubbery polymer (A) has a gel content of 80% to 100%. | 2019-12-12 |
20190375875 | HIGH MOLECULAR WEIGHT BLOCK COPOLYMERS COMPRISING REPEATING UNITS DERIVED FROM MONOMERS COMPRISING LACTAM AND ACRYLOYL MOIETIES AND HYDROPHILIC MONOMERS, COMPOSITIONS, AND APPLICATIONS THEREOF - This application provides high molecular weight block copolymers comprising at least one block A comprising repeating units derived from monomers comprising lactam and acryloyl moieties and at least one block B comprising repeating units derived from hydrophilic monomers. The application further provides compositions comprising the block copolymers and applications thereof in various industrial areas including personal care. The application furthermore provides compositions comprising colloidal particles of the block copolymers. The variables x, y, R | 2019-12-12 |
20190375876 | CURABLE COMPOSITION - A curable composition may include 100 parts by weight of a polyisobutylene-based polymer (A) having 1.2 or more (meth)acryloyl groups per molecule, 15 to 900 parts by weight of a polyisobutylene-based polymer (B) having 0.5 to 1.0 (meth)acryloyl group per molecule, and 0.001 to 50 parts by weight, per 100 parts by weight of the total weight of the polymer (A) and the polymer (B), of a polymerization initiator (C). Each of the polymer (A) and the polymer (B) may have a number average molecular weight of 500 to 500,000 as measured by size exclusion chromatography based on polystyrene standards, and a molecular weight distribution (weight-average molecular weight Mw)/(number-average molecular weight Mn) of 1.0 to 2.0. | 2019-12-12 |
20190375877 | CHEMICAL RESISTANT PUD FOR MICROFIBER NONWOVEN LEATHER APPLICATION AND THE METHOD - The present disclosure provides a polyurethane dispersion comprising a polyurethane prepolymer and an ionic surfactant. It further provides a microfiber nonwoven synthetic leather comprising a microfiber nonwoven fabric and the polyurethane dispersion. It further provides a method of preparing the microfiber nonwoven synthetic leather comprising a step of impregnating microfiber nonwoven fabrics into the polyurethane dispersion. | 2019-12-12 |
20190375878 | Hydrocarbon Blown Polyurethane Foam Formulation Giving Desirable Thermal Insulation Properties - Polyurethane/polyisocyanurate foam insulation described herein is derived from a composition that contains an organic polyisocyanate, an isocyanate reactive material containing at least about 20% by weight, based on the total weight of the composition, of an aromatic polyester polyol, a hydrocarbon blowing agent, a first catalyst selected from the group consisting of a carboxylate salt of an alkali metal, a carboxylate salt of an alkaline earth metal, a carboxylate salt of a quaternary ammonium, and combinations thereof, and a second catalyst comprising a non-reactive tertiary amine, wherein a molar ratio of the first catalyst to the second catalyst is less than about 1.25, the composition gels quickly, and the composition has an isocyanate index greater than about 175. Such an insulating foam has a ratio of thermal conductivity at 75° F. to thermal conductivity at 25° F. between about 0.98 and about 1.10. | 2019-12-12 |
20190375879 | POLYOL COMPOSITION FOR POLYURETHANE RESIN, POLYURETHANE-RESIN-FORMABLE COMPOSITION, AND COMPOSITE MATERIAL - The present application discloses a polyol composition for a polyurethane resin and a polyurethane-resin-formable composition that are capable of forming a polyurethane resin that exhibits a low resin viscosity during shaping, but has a high glass transition temperature, and a composite material. | 2019-12-12 |
20190375880 | ONE COMPONENT POLYURETHANE DISPERSION FOR VINYL WINDOWS AND OTHER SUBSTRATES - The present invention provides an aqueous polyurethane dispersion (PUD) comprising an amorphous polyester having a glass transition temperature (T | 2019-12-12 |
20190375881 | FLEXIBLE POLYURETHANE FOAM AND PROCESS TO MAKE - Disclosed is a composition and process for making a flexible polyurethane foam from a polyol mixture that contains a copolymer polyol, a polyether polyol having a functionality equal to or greater than 3, an autocatalytic polyol, a hydroxyalkyltriethylenediamine and/or a hydroxytriethylenediamine catalyst, and a tertiary amine catalyst. Said foams have excellent resiliency and low compression sets and are particularly suited for use in low emission automobile seating applications. | 2019-12-12 |
20190375882 | TOUGHENED URETHANE ACRYLATE COMPOSITIONS - In various embodiments, a resin composition includes a urethane (meth)acrylate, a reactive diluent, and a urethane (meth)acrylate toughener. The urethane (meth)acrylate toughener includes at least one additional polyol having a number average molecular weight Mn of greater than 1,000 g/mol. Cured articles made from the resin composition have an average fracture toughness (K | 2019-12-12 |
20190375883 | SKIN MATERIAL FOR COATING MOTOR VEHICLES PARTS - The present invention relates to a skin material, which is in the form of a flexible film obtained from a composition comprising at least one fluorinated polymer, and its use for coating motor vehicle parts. | 2019-12-12 |
20190375884 | Process for the Manufacture of an Epoxy-Functional Polyester, Epoxy-Functional Polyester Obtained by Such Process and Coating Composition Comprising Such Epoxy-Functional Polyester - The present invention relates to a process for the manufacture of an epoxy-functional polyester. The process according to the invention comprises the steps of a) providing a polyester having functional groups selected from hydroxyl groups and carboxylic acid groups, or mixtures thereof, b) reacting the functional groups of the polyester with an epihaloalkane to obtain an epoxy-functional polyester dissolved in a liquid phase, c) optionally adding an organic solvent to the liquid phase obtained in step b); d) precipitating the epoxy-functional polyester from the liquid phase obtained in step b) or in step c); and e) isolating the precipitated epoxy-functional polyester from the liquid phase by a solid-liquid separation technique. The thus obtained resin is in particular useful for use in powder coatings. The invention further relates to a solid epoxy-functional polyester obtainable by such process and to a coating composition, in particular a powder coating composition, comprising such solid epoxy-functional polyester. | 2019-12-12 |
20190375885 | PRODUCTION METHODS FOR GLASSY LIQUID-CRYSTALLINE EPOXY RESIN AND GLASSY LIQUID-CRYSTALLINE EPOXY RESIN COMPOSITION, STORAGE METHODS FOR LIQUID-CRYSTALLINE EPOXY RESIN AND LIQUID-CRYSTALLINE EPOXY RESIN COMPOSITION, GLASSY LIQUID-CRYSTALLINE EPOXY RESIN AND GLASSY LIQUID-CRYSTALLINE EPOXY RESIN COMPOSITION, LIQUID-CRYSTALLINE EPOXY RESIN AND LIQUID-CRYSTALLINE EPOXY RESIN COMPOSITION, AND PRODUCTION METHOD FOR CURED EPOXY RESIN - A production method for a glassy liquid-crystalline epoxy resin, comprising a process of cooling a liquid-crystalline epoxy resin to cause transition into a glassy state. | 2019-12-12 |
20190375886 | Functional Spirocyclic Polymers and Methods of Preparation Thereof - Provided herein are spirocyclic polymers that exhibit aggregation-enhanced emission properties and methods of preparation thereof. The spirocyclic polymers can be used in the construction of integrated silicon photonics and to prepare two-dimensional fluorescent photopatterns useful for the manufacture of biological sensing and probing systems, optical writing and reading, anti-counterfeiting applications and the construction of optical display devices. | 2019-12-12 |
20190375887 | POROUS COMPOSITIONS AND RELATED METHODS - Porous compositions such as flexible polymers with side chain porosity are generally provided. In some embodiments, the composition comprises a flexible polymer backbone and a plurality of rigid side chains. In some embodiments, the rigid side chains form pores. In some embodiments, the rigid side chains may comprise two or more [2.2.2] bicyclic cores (e.g., formed by a ring opening metathesis polymerization. The compounds and methods described herein may be useful in various applications including, for example, gas separation. | 2019-12-12 |
20190375888 | COMPOSITIONS USEFUL FOR THE FORMATION OF AN ANTISTATIC LAYER OR AN ELECTROMAGNETIC RADIATION SHIELD - A liquid composition. The liquid composition comprises | 2019-12-12 |
20190375889 | FOAMED COMPOSITION - The invention relates to a foamed composition comprising a thermoplastic copolyester elastomer in an amount of between 70 to 99 wt % and a plasticizer in an amount of between 1 to 30 wt % based on the total amount of the composition and articles comprising the foamed composition, as well as a process for preparing such foamed composition. | 2019-12-12 |
20190375890 | 2, 5-FURANDICARBOXYLIC ACID-BASED POLYESTERS - The invention is directed to a polyester comprising 5-furandicarboxylic acid moieties (A); ethylene glycol moieties (B); 1,4:3,6-dianhydrohexitol moieties (C); alicyclic diol moieties other than the 1,4:3,6-dianhydrohexitol moieties (D); wherein the molar ratio (B)/[(B)+(C)+(D)] is greater than 0.2. The invention aloes relates to a process of preparing the polyester and to its use. | 2019-12-12 |
20190375891 | Multifunctional Degradable Nanoparticles with Control over Size and Functionalities - In one aspect, the invention relates to polymers, crosslinked polymers, functionalized polymers, nanoparticles, and functionalized nanoparticles and methods of making and using same. In one aspect, the invention relates to degradable polymers and degradable nanoparticles. In one aspect, the invention relates to methods of preparing degradable nanoparticles and, more specifically, methods of controlling particle size during the preparation of degradable nanoparticles. In one aspect, the degradable nanoparticles are useful for complexing, delivering, and releasing payloads, including pharmaceutically active payloads. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 2019-12-12 |
20190375892 | METHODS FOR PREPARING POLYMERIC REAGENTS AND COMPOSITIONS OF POLYMERIC REAGENTS - Methods for preparing active carbonate esters of water-soluble polymers are provided. Also provided are other methods related to the active carbonate esters of water-soluble polymers, as well as corresponding compositions. | 2019-12-12 |
20190375893 | POLYAMIDE PARTICLES AND METHOD FOR PRODUCING POLYAMIDE PARTICLES - Provided are non-spherical polyamide particles having small variations in particle shape. The polyamide particles include a polyamide including repeating structural units having at least one alkylene group and at least one amide bond, wherein each of the at least one alkylene group has 1 to 3 carbon atoms. The main shape of the particles is a non-spherical shape with a circularity of less than 0.98, and a coefficient of variation (CV) of the circularity distribution is 30% or less. | 2019-12-12 |
20190375894 | POLYIMIDE FILM, LAMINATE AND SURFACE MATERIAL FOR DISPLAY - A polyimide film includes a polyimide in which a specific amount of molecular framework containing one or two silicon atoms in its main chain, wherein a total light transmittance measured in accordance with JIS K7361-1 is 85% or more; wherein a yellowness index calculated in accordance with JIS K7373-2006 is 30 or less; wherein a glass transition temperature is in a temperature range of from 150° C. to 400° C.; and wherein a tensile elastic modulus at 25° C. obtained by measuring a 15 mm×40 mm test piece at a tensile rate of 10 mm/min and a chuck distance of 20 mm in accordance with JIS K7127, is 1.8 GPa or more. | 2019-12-12 |
20190375895 | CROSSLINKED POLYMER RESIN FOR CONTAMINANT ADSORPTION FROM WATER - Cross-linked polymer resins and related salts, solvates, tautomers or stereoisomers are described herein. The cross-linked polymer resins may comprise monomer units of N,N-diallyl aminoalkylphosphonate, a hydrophobic pendant, a tetraallylpiperazinium cross-linker, and sulfur dioxide. A method for producing the cross-linked polymer resins is described. The cross-linked polymer resins may be used as adsorbent materials for the removal of heavy metal ions and contaminant dyes from aqueous solutions. Used cross-linked polymer resins may be removed from solution, cleaned, and reused while maintaining adsorption capacity. | 2019-12-12 |
20190375896 | SILSESQUIOXANE DERIVATIVE HAVING RADICAL POLYMERIZABLE FUNCTIONAL GROUP, COMPOSITION THEREOF, AND CURED FILM HAVING LOW CURE SHRINKAGE - Provided is a new compound which can provide a cured film obtained from a resin composition with low cure shrinkage while suppressing reduction of hardness (scratch resistance) thereof. A silsesquioxane derivative having a radically polymerizable functional group, which is represented by formula (1), (2) or (3). In the formulas (1) to (3), R | 2019-12-12 |
20190375897 | WATER REPELLENT AGENT COMPOSITION AND METHOD FOR PRODUCING WATER REPELLENT FIBER PRODUCT - The first water repellent agent composition contains amino-modified silicone, a silicone resin, and a polyfunctional isocyanate compound. The second water repellent agent composition comprising dimethylpolysiloxane having a hydroxyl group and/or an alkoxy group having 1 to 3 carbon atoms, an amino group-containing silane coupling agent, a silicone resin, and a polyfunctional isocyanate compound. | 2019-12-12 |
20190375898 | LIQUID BICONTINUOUS STABILIZED ASSEMBLIES BY INTERFACIAL JAMMING OF NANOPARTICLES - A method for preparing a stabilized assembly includes combining a first liquid phase including nanoparticles and a second, immiscible liquid phase, dissolving in the second phase a first end-functionalized polymer having a first molecular weight, and a second end-functionalized polymer having a second molecular weight, wherein the second molecular weight is greater than the first molecular weight, applying a shearing external deformation field to increase the surface area of the first phase to create a new interface, wherein the nanoparticle surfactants form a disordered, jammed assembly at the new interface, and releasing the shearing external deformation field. The polymer and the nanoparticles can interact at an interface through ligand interactions to form nanoparticle surfactants and upon releasing the external deformation field the jammed assembly at the new interface traps the first phase in a deformed state having the first liquid phase and the second liquid phase as interpenetrating domains. | 2019-12-12 |
20190375899 | METHODS OF MAKING AN ELASTOMER COMPOSITE REINFORCED WITH SILICA AND PRODUCTS CONTAINING SAME - Methods to make a silica elastomer composite with a destabilized dispersion of silica are described, along with silica elastomer composites made from the methods. The advantages achieved with the methods are further described. | 2019-12-12 |
20190375900 | THERMOPLASTIC STARCH COMPOSITION DERIVATIVES FROM AGRICULTURAL BYPRODUCTS - A thermoplastic starch composition acquired from compounding a mixture comprises starch-containing agricultural waste in 45 to 70% by weight of total composition that the agricultural waste contains starch content less than 50% in dry weight; thermoplastic synthetic polymer in 25 to 50% by weight of total composition; plasticizer in 1 to 10% by weight of total composition; and coupling agent in 1 to 5% by weight of total composition; wherein the compounding is performed at a first temperature which is higher than room temperature. | 2019-12-12 |
20190375901 | METHODS OF MAKING AN ELASTOMER COMPOSITE REINFORCED WITH SILICA AND PRODUCTS CONTAINING SAME - Methods to make a silica elastomer composite with a destabilized dispersion of a never-dried, or as-produced, precipitated silica are described, along with silica elastomer composites made from the methods. The advantages achieved with the methods are further described. | 2019-12-12 |
20190375902 | METHODS OF MAKING AN ELASTOMER COMPOSITE REINFORCED WITH SILICA AND CARBON BLACK AND PRODUCTS CONTAINING SAME - Methods to make a silica and carbon black elastomer composite with a destabilized dispersion that includes silica are described, along with particle reinforced elastomer composites made from the methods. The advantages achieved with the methods are further described. | 2019-12-12 |
20190375903 | FILLER-REINFORCED RESIN STRUCTURE - The present invention relates to a filler-reinforced resin structure, and the structure is a structure containing a carbodiimide-modified polyolefin (A) having a carbodiimide group content of 1 to 200 mmol/100 g; or a structure containing a carbodiimide-modified polyolefin (A) having a carbodiimide group content of 1 to 200 mmol/100 g, a polypropylene resin, and a carbon fiber, and the structure containing 0.0001 to 140 mmol of the carbodiimide group based on 100 g of resin components in the structure. | 2019-12-12 |